Review article · 2011 · Open access
Risperidone versus other atypical antipsychotics for schizophrenia
Cochrane Database of Systematic Reviews, 2013(1), CD006626 · Published 6 January 2011 · DOI 10.1002/14651858.cd006626.pub2
In brief
“Risperidone versus other atypical antipsychotics for schizophrenia” is a 2011 review article by Katja Komossa and 6 co-authors, published in Cochrane Database of Systematic Reviews. OpenAlex counts 135 citations as of 20 November 2026, which puts it in the top 5% of works published in 2011 by citations. It is open access: the full text is free to read at PubMed Central.
- Citations
- 135
- Most cited in
- 2017 (13)
- Field-weighted impact
- 1.33
- References
- 255
- Authors
- 7
Abstract
BACKGROUND: In many countries of the industrialised world second-generation ("atypical") antipsychotics (SGAs) have become the first line drug treatment for people with schizophrenia. The question as to whether and if so how much the effects of the various SGAs differ is a matter of debate. In this review we examined how the efficacy and tolerability of risperidone differs from that of other SGAs. OBJECTIVES: To evaluate the effects of risperidone compared with other atypical antipsychotics for people with schizophrenia and schizophrenia-like psychosis. SEARCH STRATEGY: 1. Electronic searching We searched the Cochrane Schizophrenia Group Trials Register (April 2007) which is based on regular searches of BIOSIS, CENTRAL, CINAHL, EMBASE, MEDLINE and PsycINFO.2. Reference searching We inspected the references of all identified studies for more trials.3. Personal contact We contacted the first author of each included study for missing information.4. Drug companies We contacted the manufacturers of all atypical antipsychotics included for additional data. SELECTION CRITERIA: We included all randomised, blinded trials comparing oral risperidone with oral forms of amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, sertindole, ziprasidone or zotepine in people with schizophrenia or schizophrenia-like psychosis. DATA COLLECTION AND ANALYSIS: We extracted data independently. For dichotomous data we calculated risk ratio (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a random-effects model. We calculated numbers needed to treat/harm (NNT/NNH) where appropriate. For continuous data, we calculated mean differences (MD), again based on a random-effects model. MAIN RESULTS: The review currently includes 45 blinded RCTs with 7760 participants. The number of RCTs available for each comparison varied: four studies compared risperidone with amisulpride, two with aripiprazole, 11 with clozapine, 23 with olanzapine, eleven with quetiapine, two with sertindole, three with ziprasidone and none with zotepine. Attrition from these studies was high (46.9%), leaving the interpretation of results problematic. Furthermore, 60% were industry sponsored, which can be a source of bias.There were few significant differences in overall acceptability of treatment as measured by leaving the studies early. Risperidone was slightly less acceptable than olanzapine, and slightly more acceptable than ziprasidone in this regard.Risperidone improved the general mental state (PANSS total score) slightly less than olanzapine (15 RCTs, n = 2390, MD 1.94 CI 0.58 to 3.31), but slightly more than quetiapine (9 RCTs, n = 1953, MD -3.09 CI -5.16 to -1.01) and ziprasidone (3 RCTs, n = 1016, MD -3.91 CI -7.55 to -0.27). The comparisons with the other SGA drugs were equivocal. Risperidone was also less efficacious than olanzapine and clozapine in terms of leaving the studies early…
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Komossa, K., Rummel‐Kluge, C., Schwarz, S., Schmid, F., Hunger, H., Kissling, W., & Leucht, S. (2011). Risperidone versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews, 2013(1), CD006626. https://doi.org/10.1002/14651858.cd006626.pub2
MLA 9
Komossa, Katja, et al. “Risperidone versus other atypical antipsychotics for schizophrenia.” Cochrane Database of Systematic Reviews, vol. 2013, no. 1, 2011, p. CD006626. https://doi.org/10.1002/14651858.cd006626.pub2.
Chicago
Komossa, Katja, Christine Rummel‐Kluge, Sandra Schwarz, Franziska Schmid, Heike Hunger, Werner Kissling, and Stefan Leucht. 2011. “Risperidone versus other atypical antipsychotics for schizophrenia.” Cochrane Database of Systematic Reviews 2013 (1): CD006626. https://doi.org/10.1002/14651858.cd006626.pub2.
Harvard
Komossa, K. et al. (2011) ‘Risperidone versus other atypical antipsychotics for schizophrenia’, Cochrane Database of Systematic Reviews, 2013(1), p. CD006626. doi:10.1002/14651858.cd006626.pub2.
IEEE
K. Komossa et al., “Risperidone versus other atypical antipsychotics for schizophrenia,” Cochrane Database of Systematic Reviews, vol. 2013, no. 1, p. CD006626, 2011, doi: 10.1002/14651858.cd006626.pub2.
BibTeX
@article{komossa2011risperidone,
title = {{Risperidone versus other atypical antipsychotics for schizophrenia}},
author = {Komossa, Katja and Rummel‐Kluge, Christine and Schwarz, Sandra and Schmid, Franziska and Hunger, Heike and Kissling, Werner and Leucht, Stefan},
journal = {Cochrane Database of Systematic Reviews},
year = {2011},
volume = {2013},
number = {1},
pages = {CD006626},
doi = {10.1002/14651858.cd006626.pub2},
url = {https://doi.org/10.1002/14651858.cd006626.pub2}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2017 | 13 | |
| 2018 | 9 | |
| 2019 | 4 | |
| 2020 | 10 | |
| 2021 | 8 | |
| 2022 | 6 | |
| 2023 | 8 | |
| 2024 | 5 | |
| 2025 | 4 | |
| 2026 | 3 |
Its field-weighted citation impact is 1.33: it has been cited 1.33 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- atypical antipsychotics
- schizophrenia
- amisulpride
- aripiprazole
- clozapine
- olanzapine
- quetiapine
- sertindole
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Komossa, K., Rummel‐Kluge, C., Schwarz, S., Schmid, F., Hunger, H., Kissling, W., & Leucht, S. (2011). Risperidone versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews, 2013(1), CD006626. https://doi.org/10.1002/14651858.cd006626.pub2
How many times has this paper been cited?
135 times, according to OpenAlex on 20 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at PubMed Central: sign in and open the full text from this page.
Who wrote this paper?
Katja Komossa, Christine Rummel‐Kluge, Sandra Schwarz, Franziska Schmid, Heike Hunger, Werner Kissling, Stefan Leucht.
What is the DOI of this paper?
10.1002/14651858.cd006626.pub2, permanently at https://doi.org/10.1002/14651858.cd006626.pub2. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 20 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.